Database→SLU-PP-332

Tier 4MetabolicPerformanceMitochondrialPREMIUM

SLU-PP-332

Estrogen-Related Receptor Pan-Agonist SLU-PP-332 (ERRalpha/beta/gamma Agonist)

Not FDA approved. Research compound only. WADA Prohibited (S4: Hormone and Metabolic Modulators). No human clinical trials initiated.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

SLU-PP-332 is a synthetic small molecule that activates all three estrogen-related receptor subtypes (ERRalpha, ERRbeta, ERRgamma), triggering a gene expression program that closely resembles the response to acute aerobic exercise. In multiple mouse studies it has increased endurance, reduced fat mass, improved insulin sensitivity, and shown protection against heart failure and age-related kidney dysfunction. No human trials have been conducted.

🔒

Full Profile: Premium Members Only

The complete SLU-PP-332 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use